Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2022

Login to access report north_east
Contact sales account_box

characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation 
predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for 
IBS, and only a few drugs have secured FDA approval for IBS-D. Current prescribing among recently treated and newly diagnosed IBS-D patients?
 * How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?
 * What percentage of IBS-D patients receive drug therapy within 365 days
*Markets covered:* United States
*Key companies:* AbbVie, Salix, Sebela Pharmaceuticals
*Key drugs:* Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate
characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation 
predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for 
IBS, and only a few drugs have secured FDA approval for IBS-D. Current    prescribing among recently treated and newly diagnosed IBS-D patients?
 * How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?
 * What percentage of IBS-D patients receive drug therapy within 365 days
*Markets covered:* United States
*Key companies:* AbbVie, Salix, Sebela Pharmaceuticals
*Key drugs:* Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate
 

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
north_east
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
north_east
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
north_east
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east